The drug is being evaluated as an oral treatment to reduce the frequency and severity of allergic reactions following exposure to peanuts in children and adolescents ages 4 to 17.
A biologics license application for the drug is under review by the US Food and Drug Administration and is expected to take until late January. The allergenic products advisory committee of the FDA will review the application at its Sept. 13 meeting.
Price: 19.92, Change: +0.30, Percent Change: +1.53
|Global Portfolio Risk Report, Monday, August 19|
|Eton Pharmaceuticals Reports Positive Results from S...|
|Market Chatter: Alphabet's Google Said to Have Shut ...|
|VMware Expected to Post Year-on-Year Growth in Fisca...|
|Target to Launch Largest-Owned Brand With 'Good & Ga...|